tiprankstipranks

Sensei Biotherapeutics Approves Reverse Stock Split

Story Highlights
Sensei Biotherapeutics Approves Reverse Stock Split

Don’t Miss TipRanks’ Half-Year Sale

The latest update is out from Sensei Biotherapeutics ( (SNSE) ).

On May 21, 2025, Sensei Biotherapeutics held its annual meeting of stockholders, where three proposals were considered. The stockholders elected two nominees to the Board of Directors, ratified the appointment of Deloitte & Touche LLP as the independent public accounting firm for 2025, and approved an amendment for a reverse stock split of common stock.

The most recent analyst rating on (SNSE) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Sensei Biotherapeutics stock, see the SNSE Stock Forecast page.

Spark’s Take on SNSE Stock

According to Spark, TipRanks’ AI Analyst, SNSE is a Underperform.

Sensei Biotherapeutics faces substantial financial challenges, with no revenue and ongoing net losses. The technical analysis indicates a bearish trend, and the valuation is poor due to negative earnings. However, the positive corporate event regarding trial results offers a glimpse of potential future success. The overall score reflects these mixed factors, with financial weaknesses being the most significant deterrent.

To see Spark’s full report on SNSE stock, click here.

More about Sensei Biotherapeutics

Sensei Biotherapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative immunotherapies for cancer treatment.

Average Trading Volume: 2,712,065

Technical Sentiment Signal: Sell

Current Market Cap: $7.55M

Learn more about SNSE stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1